HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

56.450

-1.250-2.17%

Volume:391.60K

Turnover:22.38M

Market Cap:9.60B

PE:-26.88

High:59.450

Open:57.900

Low:56.300

Close:57.700

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:0.57

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:4.75

PE(LYR):-26.88

PS:17.69

Loading ...

Overview Company News Filings

瑞博生物发布H股股权激励方案：股份总量上限17.06 million，占总股本10%

Bulletin Express

瑞博生物发布H股购股权计划：期权总量上限约1,705.55万股，占已发行股本10%

Bulletin Express

RIBOLIFE-B Calls 5 June 2026 AGM; Tables Option & Incentive Schemes, Scraps Supervisory Committee and Seeks Fresh Mandates

Bulletin Express

Ribo Life Science releases proxy details for 2025 AGM; shareholders to vote on profit distribution, equity incentives and governance overhaul

Bulletin Express

Suzhou Ribo Life Science announces annual shareholder meeting rescheduling

Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe

MT Newswires Live

RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism

RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism

Bulletin Express

Suzhou Ribo submits EMA Phase 2b trial application for vortosiran in VTE

RIBOLIFE-B Maintains 170.55 Million Issued Shares in April; Confirms Public Float Compliance

Bulletin Express

Ribo, Boehringer advance siRNA MASH drug program to third milestone

Ribo and Boehringer Ingelheim Further Progress Their Sirna Program for Metabolic Dysfunction-Associated Steatohepatitis (Mash)

THOMSON REUTERS

Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations

RIBOLIFE-B Achieves Key Development Milestone in Liver Disease Collaboration with Boehringer Ingelheim

Ribo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim

Bulletin Express

Suzhou Ribo hits third research milestone in Boehringer liver disease collaboration

RIBOLIFE-B聚焦创新药管线，2025年营收小幅增长但仍录净亏损

Bulletin Express

Suzhou Ribo Life Science publishes 2025 annual report

RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention

RIBOLIFE-B (06938) Submits Application for Phase 2b Trial of Core Product VORTOSIRAN in SPAF Indication

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/06938/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":56.45,"timestamp":1789027722334,"preClose":57.7,"halted":0,"volume":391600,"delay":0,"changeRate":-0.02166377816291161,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Not Yet Opened","change":-1.25,"latestTime":"09-10 16:08:42","open":57.9,"high":59.45,"low":56.3,"amount":22380100,"amplitude":0.054593,"askPrice":56.6,"askSize":200,"bidPrice":56.45,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":57.7,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.5718239168086074,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"volumeRatio":0.5718239168086074,"shares":170000000,"dividePrice":0,"high":59.45,"amplitude":0.054593,"preClose":57.7,"low":56.3,"week52Low":43.6,"pbRate":"4.75","psRate":"17.69","week52High":95.8,"institutionHeld":0,"latestPrice":56.45,"eps":-2.100221,"divideRate":0,"volume":391600,"delay":0,"ttmEps":-1.149,"open":57.9,"prevYearClose":57.97,"prevWeekClose":66.05,"prevMonthClose":60.25,"prevQuarterClose":46.9,"fiveDayClose":64.25,"twentyDayClose":54,"sixtyDayClose":50.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784304000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-09-09","current":-49.129678,"percent":0.065217,"low":-56.914635,"twenty":-39.334312,"median":-30.985978,"eighty":-26.650283,"high":-23.913403,"avg":-33.56676,"sd":8.013017,"marketCap":9841018307},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438},{"date":"2026-09-04","current":-56.914635,"twenty":-38.685171,"median":-30.913769,"eighty":-26.600296,"marketCap":11265151805},{"date":"2026-09-09","current":-49.640073,"twenty":-39.334312,"median":-30.985978,"eighty":-26.650283,"marketCap":9841018307}],"updateTime":1789078829431},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111399529","title":"瑞博生物发布H股股权激励方案：股份总量上限17.06 million，占总股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111399529","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111399529?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581422,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（瑞博生物）公布《H股股份激励计划》，并已提交股东大会特别决议案审批。以下为方案要点： 1. 计划规模与期限   • 计划总量：可新发行及/或由受托人购入的H股不超过17.06 million 股，占采纳日已发行股份的10%。   • 服务提供者专属子限额：0.85 million 股，占已发行股份的0.5%。   •...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107643960","title":"瑞博生物发布H股购股权计划：期权总量上限约1,705.55万股，占已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107643960","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107643960?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581420,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Biotechnology Co., Ltd.（瑞博生物，H股简称：RIBOLIFE-B）公布《H股购股权计划》草案，方案已提交股东大会审议，通过后即生效并执行期为10年。 核心条款   1. 期权池规模：本计划与其他任何股份激励计划下可发行的合计股份数上限为17,055,491股，对应当前已发行股本的10.00%。   2....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147632196","title":"RIBOLIFE-B Calls 5 June 2026 AGM; Tables Option & Incentive Schemes, Scraps Supervisory Committee and Seeks Fresh Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1147632196","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147632196?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581418,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (“RIBOLIFE-B”) has issued a circular convening its annual general meeting for 1:30 p.m. on 5 June 2026 in Beijing.  Key proposals and information are summarised...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192874107","title":"Ribo Life Science releases proxy details for 2025 AGM; shareholders to vote on profit distribution, equity incentives and governance overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=1192874107","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192874107?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581394,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. has circulated the proxy form for its 2025 Annual General Meeting, which will convene at 1:30 p.m. on Friday, 5 June 2026 at F3, 3B-2 China Resources Life Sciences...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292585","title":"Suzhou Ribo Life Science announces annual shareholder meeting rescheduling","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292585","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634292585?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:46","pubTimestamp":1778579201,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science will hold its rescheduled annual general meeting in Hong Kong on June 5, 2026.Meeting date was moved from June 9 due to administrative reasons.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8WT1zD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634780283","title":"Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2634780283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634780283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498424,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA.AU","EMA","BK1161","BK7129","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112507773","title":"RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism","url":"https://stock-news.laohu8.com/highlight/detail?id=1112507773","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112507773?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:47","pubTimestamp":1778492820,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156882324","title":"RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism","url":"https://stock-news.laohu8.com/highlight/detail?id=1156882324","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156882324?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:44","pubTimestamp":1778492646,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634240237","title":"Suzhou Ribo submits EMA Phase 2b trial application for vortosiran in VTE","url":"https://stock-news.laohu8.com/highlight/detail?id=2634240237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634240237?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:41","pubTimestamp":1778492465,"startTime":"0","endTime":"0","summary":"Suzhou Ribo submitted a Phase 2b clinical trial application to EMA for vortosiran  to prevent venous thromboembolism.Filing adds to vortosiran clinical program across thromboembolic cardiovascular indications; Phase 2a coronary artery disease study in Europe completed, Phase 2b atrial fibrillation CTA submitted to EMA in April 2026.Vortosiran targets factor XI via siRNA, aiming to reduce clot risk with lower bleeding risk than current anticoagulants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 11, 2026, and is solely responsible for the informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLc4Ct8Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109213236","title":"RIBOLIFE-B Maintains 170.55 Million Issued Shares in April; Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1109213236","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109213236?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:23","pubTimestamp":1778145801,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) filed its Monthly Return for the period ended 30 April 2026, showing no changes in share capital structure. Authorised and Issued Share Capital   •...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633191371","title":"Ribo, Boehringer advance siRNA MASH drug program to third milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2633191371","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633191371?lang=en_us&edition=fundamental","pubTime":"2026-05-07 13:42","pubTimestamp":1778132570,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science disclosed a third key milestone under its siRNA collaboration with Boehringer Ingelheim to develop a potential treatment for metabolic dysfunction-associated steatohepatitis .No clinical study results were presented, with update focused on program progression and handoff for Boehringer Ingelheim to continue development.Milestone signals continued advancement of liver-targeted RNAi approach aimed at expanding future treatment options for MASH, a large and growing market with limited effective therapies.Update reinforces strategic value of Ribo’s liver-delivery platform as a partnering asset, supporting its positioning as a research and development partner for global drugmakers through 2026 and beyond.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9pLcCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633918737","title":"Ribo and Boehringer Ingelheim Further Progress Their Sirna Program for Metabolic Dysfunction-Associated Steatohepatitis (Mash)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633918737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633918737?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:21","pubTimestamp":1778066485,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUA6Z72ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175594296","title":"Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations","url":"https://stock-news.laohu8.com/highlight/detail?id=1175594296","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175594296?lang=en_us&edition=fundamental","pubTime":"2026-05-06 09:14","pubTimestamp":1778030064,"startTime":"0","endTime":"0","summary":"Major Developments: LEADS BIOLABS-B (09887) will prioritize the clinical development of LBL-047 for Sjögren's syndrome, systemic lupus erythematosus, and dermatomyositis. ASCLETIS-B (01672) will...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","399941","BK1116","01201","BK1515","160640","01672","BK1574","BK4588","09887","06938","HK0000252152.HKD","BK1161","BK4585","000941.SH","159875","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183303096","title":"RIBOLIFE-B Achieves Key Development Milestone in Liver Disease Collaboration with Boehringer Ingelheim","url":"https://stock-news.laohu8.com/highlight/detail?id=1183303096","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183303096?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:12","pubTimestamp":1778026340,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) has announced the successful achievement of the third key milestone in its research and development partnership with Boehringer Ingelheim (BI). The collaboration focuses on...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134971944","title":"Ribo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim","url":"https://stock-news.laohu8.com/highlight/detail?id=1134971944","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134971944?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:02","pubTimestamp":1778025764,"startTime":"0","endTime":"0","summary":"On 6 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the attainment of the third key milestone in its research collaboration with Germany-based Boehringer Ingelheim. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633654975","title":"Suzhou Ribo hits third research milestone in Boehringer liver disease collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2633654975","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633654975?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:52","pubTimestamp":1778025179,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science reached third key milestone in research collaboration with Boehringer Ingelheim focused on novel therapies for liver disease, including metabolic dysfunction-associated steatohepatitis .Program remained in preclinical stage as of May 6, 2026, positioning milestone as an R&D progress marker rather than a development or commercialization inflection point.Collaboration targeted pipeline expansion for MASH, a condition linked to fibrosis, cirrhosis, liver failure, liver cancer, affecting more than 200 million people globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDLVpLRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120235638","title":"RIBOLIFE-B聚焦创新药管线，2025年营收小幅增长但仍录净亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=1120235638","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120235638?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:10","pubTimestamp":1776417031,"startTime":"0","endTime":"0","summary":"苏州瑞博生物科技有限公司（RIBOLIFE-B，香港联交所股票代码：06938）公布截至2025年12月31日止年度业绩，并在报告期内于核酸药物研发管线上取得重要进展。公司实现全年收入约人民币1.485亿元（较2024年增长4.1%），但大规模研发投入及管理开支推动全年仍录得净亏损。 经营及财务表现...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628279222","title":"Suzhou Ribo Life Science publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2628279222","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628279222?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:40","pubTimestamp":1776415202,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science published 2025 annual report highlighting pipeline progress across cardiovascular, metabolic, renal, and liver programs.Phase 2 trial for core candidate vortosiran  was basically completed, reinforcing its positioning as an FXI-targeting siRNA with long duration of effect.China Phase 2 trial for RBD5044 began in February 2026 following January 2026 clearance, supporting broader development alongside ongoing European work.Partner-led PCSK9 program RBD7022  moved toward Phase 3 initiation in China, marking first in-house-originated asset set to enter Phase 3.Report flagged strategic expansion via a Madrigal collaboration valued at more than USD 4.4 billion, alongside progress in extra-hepatic delivery research targeting kidney, heart, and adipose tissue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL525421:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UAN","06938","BK4590","BK1161","BK4093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182190562","title":"RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=1182190562","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182190562?lang=en_us&edition=fundamental","pubTime":"2026-04-15 11:33","pubTimestamp":1776224004,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK4588","VXUS","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135129754","title":"RIBOLIFE-B (06938) Submits Application for Phase 2b Trial of Core Product VORTOSIRAN in SPAF Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1135129754","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135129754?lang=en_us&edition=fundamental","pubTime":"2026-04-14 08:08","pubTimestamp":1776125301,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its core product, Vortosiran (RBD4059), has successfully submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase 2b trial...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":92,"code":"91000000","status":"200"}]}}